INTRODUCTION
 In Australia, submissions for drugs are lodged by sponsors, and the Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Minister for Health on their listing on the national Pharmaceutical Benefits Scheme (PBS). Information on the outcomes of submissions to the PBAC is made public on the Department of Health website, and, since 2005, detail provided in Public Summary Documents (PSDs). 1  The PBAC guidelines request that the submission present evidence of comparative clinical efficacy and safety as well as cost-effectiveness versus the comparator(s), which is usually the treatment(s) it is most likely to replace in practice.
 When there are no direct head-to-head trials versus an appropriate comparator, indirect comparisons via a common arm are often performed to support a clinical claim and relative pricing. 2  Often, in oncology or rare diseases, the clinical evidence for some drugs consists only of one singlearm study, excluding the possibility of a common arm comparison.
 Possible sources for data on the comparator are o baseline (pretreatment) data for the study population in the single-arm study;
o published comparator data (e.g., a single-arm study from the comparator, one arm from a randomised controlled trial, observational data); and o primary data collection (e.g., observational study or database analysis).
OBJECTIVES
To review Australian submissions that have used single-arm studies as the primary evidence to ascertain  approaches to providing comparative evidence,  their success, and  the PBAC's comments on these submissions.
METHODS
 A database of 674 PSDs published between July 2005 and December 2013 was searched for the term "single-arm" or "single arm" to identify products where there was no evidence of efficacy or safety against any other treatment. Information on the comparator(s), data source(s), clinical claim, economic analyses, PBAC concerns, and recommendations was extracted and analysed. If the submission relating to the PSD was rejected, information on outcomes from any resubmissions was sought and analysed.
RESULTS

Data set
 Twenty-two submissions used single-arm trial data as the primary clinical data to support a submission to the PBAC. Nine submissions were excluded from the data set because, while a single arm formed the basis of the submission evidence, the trial included a comparator arm (e.g., compared data from one arm of a comparative trial with external data or studies comparing two strengths of the same drug). These data were not considered to be derived from single-arm studies.
 Two additional submissions were excluded as the drugs were modifications of formulations already reimbursed based on comparative evidence.
 An additional submission (imatinib, rare diseases) was subsequently identified as presenting case series as the primary clinical data and was included in the data set. Overall, 12 submissions were included in the primary analysis. All were first-time submissions to the PBAC (Table 1) .
Economic implications
 For submissions presenting an economic evaluation, the incremental cost-effectiveness ratio (ICER) was variable: 
Outcomes
 Six of the 12 drugs were recommended for reimbursement, of which 5 claimed superiority over the comparator. Three of the submissions that were initially rejected received positive recommendations for reimbursement after a resubmission (Table 2) .
 High clinical need or evidence of effectiveness in other indications were the factors associated with a positive recommendation.
 Four of the nine drugs approved were for new listings; five were already listed for other indications.
Other single-arm submissions
 PSDs for eight additional products used a single arm of a comparative study to compare with the submission comparator treatment. In general, these submissions used similar techniques to those included in this study. Cetuximab used analysis of the Medicare Australia claims database to estimate survival in patients with colorectal cancer. 15  Since the initial search, there have been further positive recommendations for products based on a primary evidence base of a single-arm study(s): brentuximab for systemic anaplastic large cell lymphoma, 16 denosumab for giant cell tumours, 17 and betaine for the treatment of homocystinuria. 18 
STUDY LIMITATIONS
 Information contained in the PSDs on the evidence base for some products is incomplete.
 Similarly, public information on some submissions is not available, and submissions included with a recommendation to reject may be resubmitted in the future.  While expressing concerns regarding the quality of the comparative evidence, the PBAC accepted the evidence base in the majority of cases.
 Of the nine products that were eventually approved, only five were listed for other indications-suggesting that while this may be helpful, it was not a prerequisite.
 The PBAC's acceptance of single-arm studies as the primary clinical evidence for drug reimbursement submissions may reflect an appreciation of the practical and ethical challenges of undertaking comparative studies in some patient populations. Establishing comparative efficacy and safety  Nine submissions used published data to estimate the comparator's effectiveness and safety. The majority of these publications reported on outcomes from observational studies or other single-arm studies of the comparator.
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 Two submissions presented data that appeared to have been collected to inform the submission.
 Three submissions presented no comparator data. Efficacy and safety appears to have been inferred from pre-and post-treatment differences for two of these.
 Eleven submissions claimed superior efficacy and/or safety over the comparator.
